CA2767711A1 - Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis - Google Patents

Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis Download PDF

Info

Publication number
CA2767711A1
CA2767711A1 CA2767711A CA2767711A CA2767711A1 CA 2767711 A1 CA2767711 A1 CA 2767711A1 CA 2767711 A CA2767711 A CA 2767711A CA 2767711 A CA2767711 A CA 2767711A CA 2767711 A1 CA2767711 A1 CA 2767711A1
Authority
CA
Canada
Prior art keywords
patient
lesions
patients
multiple sclerosis
teriflunomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2767711A
Other languages
English (en)
French (fr)
Inventor
William Byrnes
Patrice Douillet
Gerald Frangin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41283539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2767711(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis US LLC filed Critical Sanofi Aventis US LLC
Publication of CA2767711A1 publication Critical patent/CA2767711A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2767711A 2009-07-10 2010-07-08 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis Abandoned CA2767711A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP09305669A EP2277515A1 (en) 2009-07-10 2009-07-10 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
EP09305669.5 2009-07-10
US22534209P 2009-07-14 2009-07-14
US61/225,342 2009-07-14
US28614809P 2009-12-14 2009-12-14
US61/286,148 2009-12-14
US35095710P 2010-06-03 2010-06-03
US61/350,957 2010-06-03
PCT/US2010/041274 WO2011005907A1 (en) 2009-07-10 2010-07-08 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
CA2767711A1 true CA2767711A1 (en) 2011-01-13

Family

ID=41283539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2767711A Abandoned CA2767711A1 (en) 2009-07-10 2010-07-08 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis

Country Status (20)

Country Link
US (2) US20120107277A1 (es)
EP (2) EP2277515A1 (es)
JP (1) JP2012532881A (es)
KR (1) KR20120050976A (es)
CN (1) CN102470116A (es)
AR (1) AR077460A1 (es)
AU (1) AU2010271467A1 (es)
BR (1) BR112012000490A2 (es)
CA (1) CA2767711A1 (es)
CL (1) CL2012000062A1 (es)
CO (1) CO6491023A2 (es)
IL (1) IL217434A0 (es)
MA (1) MA33515B1 (es)
MX (1) MX2012000458A (es)
RU (1) RU2012104666A (es)
SG (1) SG177544A1 (es)
TW (1) TW201106945A (es)
UY (1) UY32781A (es)
WO (1) WO2011005907A1 (es)
ZA (1) ZA201108340B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973119T3 (es) * 2018-10-09 2024-06-18 Medicinova Inc Combinación de ibudilast e interferón-beta y métodos de uso

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
DE60226855D1 (de) * 2001-04-05 2008-07-10 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
AU2005295511A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Also Published As

Publication number Publication date
IL217434A0 (en) 2012-02-29
KR20120050976A (ko) 2012-05-21
CO6491023A2 (es) 2012-07-31
EP2451449A1 (en) 2012-05-16
ZA201108340B (en) 2012-07-25
US20120107277A1 (en) 2012-05-03
EP2277515A1 (en) 2011-01-26
BR112012000490A2 (pt) 2016-02-16
TW201106945A (en) 2011-03-01
AR077460A1 (es) 2011-08-31
EP2451449B1 (en) 2014-05-07
CL2012000062A1 (es) 2012-10-05
MA33515B1 (fr) 2012-08-01
RU2012104666A (ru) 2013-08-20
US20130156735A1 (en) 2013-06-20
JP2012532881A (ja) 2012-12-20
SG177544A1 (en) 2012-03-29
WO2011005907A1 (en) 2011-01-13
UY32781A (es) 2011-02-28
CN102470116A (zh) 2012-05-23
MX2012000458A (es) 2012-01-27
AU2010271467A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
DK2533634T3 (en) NEURO PROTECTIVE demyelinating diseases
EP2879672B1 (en) Combination therapy for treatment of multiple sclerosis
CA2443285C (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
JP2001515047A (ja) コンセンサスインターフェロンを使用する多発性硬化症患者の治療方法
US6794410B2 (en) Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP2451449B1 (en) Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
US9060994B2 (en) Combination therapy with interferon and andrographolides for Multiple Sclerosis
EP2314291A1 (en) Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
CA2778256A1 (en) Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
Alam Interferon-β treatment of human disease
Ríos-Garcés et al. Targeting interferon I in SLE: A promising new perspective
RU2019134182A (ru) Новые способы лечения рассеянного склероза
EP1471974B1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases
CN103845726A (zh) 克拉屈滨和乙酸格拉默的组合用于治疗多发性硬化的用途
CN113855670A (zh) A205804在制备治疗脓毒症药物中的应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140708